Home › Funds › Convergence Investment Partners, LLC › NBIX

Convergence Investment Partners, LLC position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Convergence Investment Partners, LLC reported holding 53,047 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$7.5M, representing 0.56% of its reported portfolio and ranking #47 among its reported holdings. Convergence Investment Partners, LLC has disclosed NBIX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)53.05K sh
Reported value held$7.52M
Portfolio Weight0.56%
First reportedQ2 2026
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Convergence Investment Partners, LLC's NBIX position evolved

Convergence Investment Partners, LLC first disclosed a stake in NBIX in Q2 2026 at 32,433 shares (US$5.5M). The position peaked in Q3 2026 at 53,047 shares, worth US$7.5M. Across 2 filings, Convergence Investment Partners, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 53,047 shares valued at US$7.5M — an increase of 20,614 shares quarter over quarter.. Notable position changes include a 64% increase in Q3 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 32.43K $5.47M New
Q3 2026 53.05K $7.52M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 30 other funds we track also report a position in NBIX — the largest reported positions include Two Sigma Investments (US$349.9M), Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Convergence Investment Partners, LLC held NBIX?

Convergence Investment Partners, LLC has disclosed NBIX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Convergence Investment Partners, LLC's current position in NBIX?

As of Q3 2026, Convergence Investment Partners, LLC holds 53.05K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $7.52M, representing 0.56% of its reported portfolio and ranking #47.

Has Convergence Investment Partners, LLC been buying or selling NBIX?

In the latest 13F filing (Q3 2026), Convergence Investment Partners, LLC increased its position in NBIX. The position peaked in Q3 2026 at 53.05K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Two Sigma Investments, Renaissance Technologies, Vestal Point Capital, LP, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.